Anaphylactoid reactions / anaphylaxis (includes anaphylactic shock)
- (2015): Jares EJ+, J Allergy Clin Immunol Pract 3(5), 78058%
Angioedema (formerly named angioneurotic edema)
- (2017): Dona I+, Allergy 72(9), 1346
- (2014): Dona I+, J Investig Allergol Clin Immunol 24(3), 143
Cutaneous adverse reaction (includes severe cutaneous adverse drug reaction (SCAR))
- (2021): James J+, Curr Drug Saf Oct, Online ahead of print
DRESS syndrome (Drug-induced hypersensitivity syndrome)
- (2017): Matta JM+, An Bras Dermatol 92(1), 30 [REVIEW] (passim)
- (2015): Farshchian M+, Clin Cosmet Investig Dermatol 8, 539%
Fixed eruption / fixed drug eruption
- (2015): Farshchian M+, Clin Cosmet Investig Dermatol 8, 5316%
- (2014): Dona I+, J Investig Allergol Clin Immunol 24(3), 143 [REVIEW]
Lupus erythematosus (subacute cutaneous lupus erythematosus (SCLE))
- (2012): Dalle Vedove C+, J Dtsch Dermatol Ges 10(12), 889 [REVIEW]
- (2017): Lugovic-Mihic L+, Acta Clin Croat 56(2), 277 [REVIEW]
- (2016): Del Vecchio L+, Expert Opin Drug Saf May, Epub ahead of print [REVIEW]
- (2016): Zuba EB+, Acta Dermatovenerol Croat 24(1), 55 [REVIEW]
- (2017): Eccleston C+, Cochrane Database Syst Rev 8, CD012537 [REVIEW]
Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN)
- (2022): Shao QH+, Front Pediatr May (e-Collection) (pharmacovigilance)
- (2011): Barvaliya M+, J Postgrad Med 57(2), 11522%
- (2011): Ferrandiz-Pulido C+, Med Clin (Barc) 136(13), 583
Toxic epidermal necrolysis (Lyell's syndrome)
- (2011): Barvaliya M+, J Postgrad Med 57(2), 11522%
- (2011): Ferrandiz-Pulido C+, Med Clin (Barc) 136(13), 583
- (2023): Miniello A+, Endocr Metab Immune Disord Drug Targets Sep, Online ahead of print [REVIEW]
- (2017): Dona I+, Allergy 72(9), 1346
- (2015): Farshchian M+, Clin Cosmet Investig Dermatol 8, 5327%
- (2014): Dona I+, J Investig Allergol Clin Immunol 24(3), 143